ArticleFrontiers in oncology2025
Brian [18F]FDG PET associations of cervical cancer-related peripheral inflammatory markers.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to explore brain metabolic correlates of peripheral inflammatory markers in patients with cervical cancer (CC). Methods: Cervical cancer (CC) patients (267) without treatments who underwent [18F] Fluorodeoxyglucose ([18F]FDG) positron-emission tomography (PET)/computed tomography (CT) were retrospectively studied. All CC patients were grouped into the International Federation of Gynecology and Obstetrics (FIGO) stage II (n=16), the FIGO stage III (n=160), and the FIGO stage IV (n=91) according to the FIGO stage. According to the median of metabolic tumor volume (MTV) or total lesion glycolysis (TLG) for primary tumor in different FIGO stage, CC patients in different FIGO stage were grouped into the Low_MTV (TLG) group (<median) and High_MTV (TLG) group (≥median). Regression analysis were used to explore the relationships between regional brain glucose metabolism and peripheral inflammatory markers [including Neutrophil-to-Lymphocyte ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Monocyte-to-Lymphocyte ratio (MLR), and systemic immune-inflammation index (SII)] in whole group, subgroups in different FIGO stage. Results: The MTV and TLG for primary tumor positively correlated with SII ( Conclusion: The glucose metabolism in the dlPFC negatively correlated with peripheral inflammatory markers in CC patients with FIGO stage III or IV may be relevant in the disease severity and vary depending on the disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.